MeiraGTx Says FDA Grants Breakthrough Therapy Designation For AAV2- hAQP1 For Treatment Of Grade 2 And Grade 3 Late Xerostomia Caused By Radiotherapy For Cancers Of Upper Aerodigestive Tract

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

Comments

No comments yet. Be the first!